Erivedge
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Vismodegib (Erivedge®), a hedgehog pathway inhibitor, is approved to treat metastatic or locally advanced basal cell carcinoma…
B lokal fortgeschrittenen oder multiplen BCC stoßen operative oder strahlentherapeutische Strategien o an ihre Grenzen. Bei…
Basal cell carcinomas are the most common skin cancers. They are usually localised and carry a good prognosis. There is no…
L DermaMedEst, s. r. o., Praha
Bazocelularni karcinom (bazaliom, BCC) představuje nejcastějsi nemelanomový kožni nador, s…
Introduction: Basal cell carcinoma (BCC) is the most common human malignancy. Treatment options for the minority of patients…
Basal-cell carcinoma (BCC) is the most commonly diagnosed malignancy, comprising over 80 per thousand of non-melanoma skin…
As electrical signals course through brain cells, a stepwise process of information transfer ensures that the signals are relayed…
Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge™) is a novel first-in…